GLP-1 Is Not Just Shrinking the Grocery Basket — It Is Reshaping It

The industry thinks GLP-1s are a volume story. That’s the least interesting part.

People eat less, baskets get smaller, and certain categories lose share — that much is true. At Pogo, we identified 12,000+ verified GLP-1 purchasers through transaction data, then interviewed 25 of those consumers and 15 clinicians on video. Some categories are collapsing. Others are quietly growing. And the driver is less obvious than you'd think.

Snacks and Sweets Fall First — and Hard

One of the clearest patterns across both groups was how sharply certain categories dropped. Cookies, candy, chips, sugary snacks — for many of the consumers we spoke to, these didn't taper off gradually. Cravings faded, and the categories went with them.

"The cookies, the chips, the sweets, they've all drastically dropped," one consumer told us. "Why? Because I just don't crave them anymore. I don't have the urge to eat them, and why get them if I'm not gonna eat them?"

Another had made Christmas cookies in December — and by March, they were still sitting untouched in her kitchen. Not everyone described a complete cutoff — one consumer told us she still buys a candy bar occasionally but eats half and puts the rest away — but the direction was consistent.

What sets this apart from typical dieting is the physical component. Several consumers described foods they once enjoyed now triggering nausea. Clinicians told us their patients often try fast food "quite a few times" before accepting their body won't tolerate it. The intolerance is physical, not a matter of willpower. Alcohol showed a similar pattern — clinicians reported that people on GLP-1 medications feel the effects faster and experience bloating, so many simply drink less without ever deciding to.

That said, clinicians also noted that not all their patients shift to healthier options — some simply eat less of the same foods they were eating before.

Behind It All: “Food Noise” Goes Quiet

This was probably the most important finding for anyone trying to understand the category shifts, and it is worth sitting with for a moment.

Nearly every consumer described what they called "food noise" — a constant pull toward food, thinking about the next snack, grazing out of habit rather than hunger. The medication quiets it.

"My appetite is less and I no longer have the food noise always in my head about what's to eat next," one told us. Another described it as one of the best effects of the medication: "quieting the food noise in my head so that I'm not constantly thinking about food."

Once that background noise fades, you start to notice it everywhere. Meals get planned rather than improvised, grocery trips shrink, and impulse purchases dry up along with late-night snacking.

This is why the decline hits impulse-driven categories hardest. Consumers don't decide to eat fewer cookies. They stop thinking about cookies at all. And that distinction matters — suppressed appetite can reverse when someone stops the medication, but when the cognitive pull toward food goes quiet, those habits might stick around after the medication stops.

Other Categories Are Growing

Greek yogurt stood out more than anything. Roughly half the consumers we interviewed mentioned it as a new or significantly increased purchase — used for breakfast, snacks, and as a protein-dense dessert base. Protein bars, lean meats, fresh produce, nuts, and supplements also came up repeatedly.

Clinicians described a similar pattern. Protein-focused eating was the most consistent category-level increase they observe. Hydration products — particularly electrolyte-enhanced drinks — also picked up, driven by medication side effects.

The money doesn't disappear from the grocery aisle. It moves.

Household-Level Data Hides the Individual Shift

Many of the consumers we spoke with shop for families, not just themselves. One woman buying for a family of six told us her grocery basket "still looks semi-similar" because, as she put it, "having a bunch of teenagers in the house means our grocery bill hasn't changed."

Other families described the same dynamic — the household cart stays roughly the same while the individual diet inside it changes dramatically. If you're measuring GLP-1's impact at the household level through scanner data, you're likely underestimating how far individual purchasing has already shifted.

Will It Stick?

Almost everyone we spoke to worried about this. The worry isn't hypothetical, either — consumers who had paused or stopped the medication confirmed that cravings return quickly. One told us she would "probably binge on a lot of sugars" if the medication went away. Another described her "desire for food coming back at full force" from a previous break.

Clinicians framed it in stark terms. When people discontinue, one told us, two things tend to happen: either they maintain their new eating habits, or they revert to previous patterns and regain everything. That reversion can happen within a week or two. The primary reason people stop is cost — insurance gaps, high price points, and coverage denials — not because the medication stops working or because they choose to quit.

The industry keeps modeling GLP-1 as a steady downward pressure on food volume. We think that's the wrong frame. The impact is more likely to move in waves — expanding as adoption grows, contracting as people cycle off due to cost, then expanding again as access improves. Brands planning around a linear decline may be caught off guard.

Getting the Data Right

Any strategic response to these shifts is only as good as the respondent pool behind it. Traditional research panels can screen for GLP-1 users, but self-reported survey data alone cannot confirm whether someone actually purchased or remained on the medication. In a category this personal and this stigmatized, that gap matters.

We verified every participant through real transaction data, then ran AI-moderated video interviews to understand not just what changed, but why. The full findings are available at joinpogo.ai.